We are proud to announce that PhenoPath is now a Quest Diagnostics Company.
Gliomas are the most common primary neoplasm of the central nervous system and can have strikingly different clinical behaviors and responses to therapy. Distinguishing between different subtypes is often less than perfect with significant inter-observer variability. Although attempts have been made to define clinical and histologic features that correlate with a favorable prognosis, none have been sufficiently reliable at predicting response to adjuvant chemotherapy. However, recent studies have shown that loss of 1p36 and 19q13 are associated with an oligodendroglial phenotype, favorable response to chemotherapy and overall prolonged survival. Fluorescence in-situ hybridization (FISH) studies provide a direct method for identifying loss of 1p36 and 19q13 in formalin-fixed, paraffin-embedded tissue sections. Loss of 1p36 and 19q13 is detected by assessing the ratio of 1p36 and 19q13 to their corresponding reference genes, 1q25 and 19p13, respectively, and by assessing the number of nuclei showing clear 1p36 and 19q13 deletion, according to guidelines defined by the International Society of Pediatric Oncology (ISPO). Probe type: Dual color enumeration (x2)
Disease State: Oligodendroglioma
CPT Code(s): 88374x2 (reference only; CPTs may vary)
Turnaround Time: Within 4-6 business days of receipt
Schedule: Monday, Tuesday, Wednesday, Friday
• Formalin-fixed, paraffin-embedded tissue block or cell block - OR - • Minimum of 5 unstained slide cut at 4µm for each test requested